Aristolochic acid
This article was originally published in The Tan Sheet
Executive Summary
FDA reiterates plea for health professionals to review cases of "unexplained" renal disease, urothelial tract tumors to determine if patients used supplements. In statement published in June 6 JAMA, Acting Principal Deputy Director Bernard Schwetz, PhD, says related cases should be reported "as soon as possible" to agency's MedWatch program. FDA outlined concerns regarding aristolochic acid-containing supplements in three separate letters to health professionals, consumers and industry in early April (1"The Tan Sheet" April 16, p. 9)